Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

선천성 유미흉의 임상적 고찰과 옥트레오타이드 치료

A clinical study of congenital chylothorax and octreotide therapy

  • 오웅건 (관동대학교 의과대학 제일병원 소아청소년과) ;
  • 최경은 (관동대학교 의과대학 제일병원 소아청소년과) ;
  • 김경아 (관동대학교 의과대학 제일병원 소아청소년과) ;
  • 고선영 (관동대학교 의과대학 제일병원 소아청소년과) ;
  • 이연경 (관동대학교 의과대학 제일병원 소아청소년과) ;
  • 신손문 (관동대학교 의과대학 제일병원 소아청소년과)
  • Oh, Ung Geon (Department of Pediatrics, Cheil General Hospital & Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Choi, Kyoung Eun (Department of Pediatrics, Cheil General Hospital & Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Kim, Kyung Ah (Department of Pediatrics, Cheil General Hospital & Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Ko, Sun Young (Department of Pediatrics, Cheil General Hospital & Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Lee, Yeon Kyung (Department of Pediatrics, Cheil General Hospital & Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Sin, Son Moon (Department of Pediatrics, Cheil General Hospital & Women's Healthcare Center, Kwandong University College of Medicine)
  • 투고 : 2008.05.12
  • 심사 : 2008.09.07
  • 발행 : 2008.11.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적: 선천성 유미흉은 림프관의 발달이상이나 분만시 외상으로 림프관에 손상이 가해져 유미가 흉관에 새어 나와 흉강 내에 고이는 것으로 설명되지 않는 태아수종의 흔한 원인이 되기도 한다. 본 연구에서는 산전 진단된 태아수종 중 원인질환이 유미흉으로 밝혀진 6예에 대해서 주산기내력, 임상양상, 진단, 치료 및 결과에 관하여 살펴보고, 장간막 혈류를 줄이는 효과를 갖고 있는 somatostatin 유사체인 octreotide의 사용이 치료에 미치는 영향에 대하여 알아보고자 하였다. 방 법: 2004년 1월부터 2007년 7월까지 3년 6개월간 관동대학교 의과대학 제일병원에서 출생한 27,907명의 신생아 중 태아수종을 동반한 선천성 유미흉으로 진단된 6명의 환아들의 의무기록을 후향적으로 조사하였다. 모유 또는 조제분유 수유전과 후의 흉강천자액을 분석하여 유미흉으로 확진하였고 금식, MCT milk, 인공환기기, 흉관삽입 등의 보존적 치료로 완치되었던 3예와 유미흉이 지속되어 octreotide를 사용했던 3예의 분만 형태, 진단시 검사 소견, 치료 방법, 합병증 및 임상경과를 조사하였다. 결 과: 선천성 유미흉은 0.021%의 발생률을 보였으며, 6예 모두 산전검사에서 양수 과다, 흉막 삼출 및 복수가 관찰되어 태아수종으로 진단되었다. 재태 연령은 33주에서 36주 4일이었고 평균체중은 $3,057{\pm}557g$ (2,200-3,805 g), 아프가 점수 1분 $3.0{\pm}1.1$점(1-4점), 5분 $5.7{\pm}2.0$점(5-7점)으로 모두 제왕절개로 분만하였으며, 흉막삼출은 양측성이 6예, 여아에서 4예가 관찰되었다. 흉강천자액의 분석에서 6예 모두 림프구는 92% 이상이었고, TG는 출생직후 삼출액에서 경관수유 후 유미액으로 바뀌면서 200 mg/dL 이상으로 상승되었다. 인공호흡기, 보존적 치료와 흉관삽입으로 치료하여 이중 3예(50%)가 $26.3{\pm}6.4$일(19-30일) 동안 치료받고 퇴원하였고, 나머지 3예(50%)는 유미흉이 지속되어 octreotide로 치료하였으며 평균 입원기간은 $57.7{\pm}16.2$일(39-68일)이었다. Octreotide는 평균 $18{\pm}9$일 동안 1-10 mcg/kg/hr 주입속도로 정맥내 주사하였으며, 3명 모두 완치 후 퇴원하였다. 외과적 치료가 필요하였던 환아는 없었으며, 치료 중 기흉 1명, 저알부민혈증 2명이 관찰되었고, octreotide 사용시에 1예에서 경한 구토증상만 보였지만 다른 부작용은 관찰되지 않았다. 결 론: 본 연구결과와 같이 octreotide는 보존적 치료에 잘 치료되지 않는 선천성 유미흉에 대해서 좋은 치료약제로 고려될 수 있을 것이다. 그러나, octreotide 치료의 주입방법, 용량, 치료시작 및 사용기간 등에 대한 정확한 가이드라인이 정립되어 있지 않으므로 이에 대한 연구가 더 필요할 것이며, 또한 octreotide의 좀 더 빠른 치료시작시기가 치료결과에 어떤 영향을 끼치는지에 대해서도 더 많은 연구가 필요할 것으로 사료된다.

Purpose : Congenital chylothorax is an accumulation of lymphatic fluid within the pleural space. It is a common cause of unidentified hydrops fetalis. We examined the perinatal history, clinical manifestation, diagnosis, treatment, and outcome in 6 newborns diagnosed to have congenital chylothorax with hydrops fetalis. We also studied the effect of octreotide therapy for congenital chylothorax in relation to conservative treatment. Methods : We retrospectively reviewed the medical records of 6 patients diagnosed to have congenital chylothorax with hydrops fetalis among 27,907 newborns who were born at the Cheil General Hospital and Womens Healthcare Center between January 2004 and July 2007. The diagnosis of chylothorax is based on the analysis of pleural fluid before and after milk feeding. Results : Incidence of congenital chylothorax in this study was 0.021%. All 6 cases were noted in over the 92% lymphocyte in pleural analysis. Transudate was changed into chyle with increasing triglyceride levels above 200 mg/dL after milk feeding. Three of 6 infants improved with conservative treatment, including thoracostomy and assisted ventilation. The others had persistent symptoms despite conservative treatment and responded to octreotide therapy. A complication, specifically vomiting was noted in 1 case during octreotide therapy. Conclusion : In this study, octreotide therapy resulted in a safe and excellent outcome. Therefore, octreotide therapy is considered in severe refractory congenital chylothorax in conservative treatment. Further studies are required to determine appropriate guidelines for octreotide therapy.

키워드

참고문헌

  1. Glenna B. Winnie. Chylothorax. In: Robert MK, Richard EB, Hal BJ and Bonita FS, editors. Nelson Textbook of pediatrics. 18th ed. Philadelphia : W.B. Saunders Co, 2007:1839-40
  2. Van Straaten HM, Gerards LJ, Krediet TG. Chylothorax in the neonatal period. Eur J Pediatr 1993;152:2-5
  3. Scott AL, Thomas JM and Roberta AB. Nonimmune Hydrops. In : H. William Taeusch, Roberta A. Ballard and Christine A Gleason. Editors. Averys Diseases of the Newborn. 8th ed. Philadelphia : Elsevier Saunders, 2005:63-70 https://doi.org/10.1038/sj.jp.7211200
  4. Lamberts SWJ, Van der Lely AJ, Hofland LJ. New somatostatin analogs : Will they fulfill old promises? Eur J Endocrinol 2002;146:701-5 https://doi.org/10.1530/eje.0.1460701
  5. Beghetti M, La scala G, Belli D, Bugmann P, Kalangos A, Le Coultre C. Etiology and management of pediatric chylothorax. J Pediatr 2000;136:653-8 https://doi.org/10.1067/mpd.2000.104287
  6. Mussat P, Dommergues M, Parat S, Mandelbrot L, de Gamarra E, Dumez Y, Moriette G. Congenital chylothorax with hydrops. Postnatal care and outcome following antenatal diagnosis. Acta Paediatr 1995;84:749-55 https://doi.org/10.1111/j.1651-2227.1995.tb13749.x
  7. Gustavo R. Pleural effusions in the neonate. Curr Opin Pulm Med13:305-11 https://doi.org/10.1097/MCP.0b013e3281214459
  8. Thomas NH, Anthony C and Roberta AB. Disorders of the chest wall, pleural cavity and diaphragm. In : H. William Taeusch, Roberta A. Ballard and Christine A Gleason Editors. Averys Diseases of the Newborn. 8th ed. Philadelphia : Elsevier Saunders, 2005:759-78
  9. Miller JI. Diagnosis and management of chylothorax. Chest Surg Clin N Am 1996;6:139-48
  10. Staats BA. Ellefson RD, Budahn LL, Dines DE, Prakash UB, Offord K. The lipoprotein profile of chylous and unchylous pleural effusion. Mayo Clin Proc 1980;55:700-4
  11. Gonen R, Degani S, Kugelman A, Abend M, Bader D. Intrapartum drainage of fetal pleural effusion. Prenat diagn 1999;19:1124-6 https://doi.org/10.1002/(SICI)1097-0223(199912)19:12<1124::AID-PD717>3.0.CO;2-W
  12. Picone O, Benachi A, Mandelbrot L, Ruano R, Dumez Y, Dommergues M. Thoracoamniotic shunting for fetal pleural effusions with hydrops. Am J Obstet Gynecol 2004; 191: 2047-50 https://doi.org/10.1016/j.ajog.2004.05.016
  13. Wasmuth-Pietzuch A, Hansmann M, Bartmann P, Heep A. Congenital chylothorax: Lymphopenia and high risk of neonatal infections. Acta Paediatr 2004;93:220-4 https://doi.org/10.1080/08035250310007312
  14. Jensen GL, Mascioli EA, Meyer LP, Lopes SM, Bell SJ, Babayan VK, et al. Dietary modification of chyle composition in chylothorax. Gastroenterology 1989;97:761-5 https://doi.org/10.1016/0016-5085(89)90650-1
  15. Robinson CL. The management of chylothorax. Ann Thorac Surg 1985;39:90-5 https://doi.org/10.1016/S0003-4975(10)62531-3
  16. Teba L, Dedhia HV, Alexander JC. Chylothorax review. Crit Care Med 1985;13:49-52 https://doi.org/10.1097/00003246-198501000-00013
  17. Mulvihill S, Pappas TN, Passaro E, Jr EP, Debas HT. The use of somatostatin and its analogs in the treatment of surgical disorders. Surgery 1986;100:467-75
  18. Siafakas C, Fox VL, Nurko S. Use of octreotide for the treatment of severe gastrointestinal bleeding in children. J. Pediatric Gastroenterol. Nutr 1998;26:356-9 https://doi.org/10.1097/00005176-199803000-00022
  19. Tauber MT, Harris AG, Rochiccioli P. Clinical use of the long acting somatostatin analogue octreotide in pediatrics. Eur J Pediatr 1994;153:304-10 https://doi.org/10.1007/BF01956407
  20. Lamberts SWJ, van der Lely AJ de Herder WW, Hofland LJ. Drug therapy: Octreotide. N Engl J Med 1996;334:246-54 https://doi.org/10.1056/NEJM199601253340408
  21. Glaser B, Hirsch HJ, Landau H. persistent hyperinsulinemic hypoglycemia of infancy: long-term octreotide treatment without pancreatectomy. J Pediatrics 1993;123:644-50 https://doi.org/10.1016/S0022-3476(05)80970-9
  22. Ulibarri Jl, Sanz Y, Fuentes C, Mancha A, Aramendia M, Sanchez S. Reduction of lymphorrhagia from ruptured thoracic duct by somatostatin. Lancet 1990;336:258
  23. Au M, Weber TR, Fleming RE. Successful use of somatostatin in a case of neonatal chylothorax. J Pediatr Surg 2003;38:1106-7 https://doi.org/10.1016/S0022-3468(03)00205-7
  24. Davis SN, Granner DK. Insulin, oral hypoglycaemic agents and the pharmacology of the endocrine pancreas. In : Gilmand AG, Hardman JG, Limbird LE, Molionaff PB, Ruddon RW, eds. Goodman and Gilmans the pharmacological Basic of Therapeutics, 9th edn. New York : Pergamon Press, 1996;1512-3
  25. Rasiah SV, Oei J, Lui K. Octreotide in the treatment of congenital chylothorax. J Paediatr Child Health 2004;40:585-8 https://doi.org/10.1111/j.1440-1754.2004.00471.x
  26. Tibballs J, Soto R, Bharucha T. Management of newborn lymphangiectasia and chylothorax after cardiac surgery with octreotide infusion. Ann Thoracic Surg 2004;77:2213-5 https://doi.org/10.1016/S0003-4975(03)01423-1
  27. Lam JC, Aters S, Tobias JD. Initial experience with octreotide in the pediatric population. Am J therapeutics 2001;8: 409-15 https://doi.org/10.1097/00045391-200111000-00005
  28. Ahn YJ, Jeon YH, Kim SS, Park JO, Kim CH. Treatment of congenital chylothorax in a premature infant using octreotide. J Korean Soc Neonatol 2006;13:261-6
  29. Sylvia LY and David SY Lam. spontaneous neonatal chylothorax treated with octreotide in turkey. J perinatol 2004; 24:261-2 https://doi.org/10.1038/sj.jp.7211052
  30. Brown AP, John Kattwinkel, Rodgers BM, Michalsky MP. The use of octreotide to treat congenital chylothorax. J Pediatr Surg 2006;41:845-7 https://doi.org/10.1016/j.jpedsurg.2005.12.041
  31. Pettitt TW, caspi J, Borne A. Treatment of persistent chylothorax after Noorwood procedure with somatostatin. Ann Thorac Surg 2002;73:977-9 https://doi.org/10.1016/S0003-4975(01)03014-4
  32. Buettiker V, Hug MI, Burger R , baenziger O. Somatostatin : A new therapeutic option for the treatment of chylothorax. Intensive Care Med 2001;27:1083-6 https://doi.org/10.1007/s001340100959
  33. Choi EJ, Lee S. Two cases of postoperative chylothorax treated with parenteral octreotide and conservative therapy. Korean J Pediatr 2007;50:298-301 https://doi.org/10.3345/kjp.2007.50.3.298
  34. Lee WY, Park JW, Park SH, Lee JW, Hong KW, Chil YJ. Conservative management of postoperative chylothorax using octreotide. Korean J Thorac Cardiovasc Surg 2005;38:172-4
  35. Yasin sahin and Derya Aydin. Congenital Chylothorax Treated with Octreotide. Indian J Pediatr 2005;72:885-8 https://doi.org/10.1007/BF02731124

피인용 문헌

  1. Somatostatin Treatment in Two Cases of Chyle Fistula after Neck Dissection vol.55, pp.11, 2008, https://doi.org/10.3342/kjorl-hns.2012.55.11.724